Canada Life
PTGX icon

Canada Life’s Protagonist Therapeutics PTGX Stock Holding History

Canada Life’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.88M Buy
48,045
+605
+1% +$63.2K 0.01% 715
2026
Q1 		$5M Sell
47,440
-2,200
-4% -$195K 0.01% 750
2025
Q4 		$4.33M Buy
49,640
+1,233
+3% +$101K 0.01% 808
2025
Q3 		$3.15M Sell
48,407
-1,835
-4% -$104K ﹤0.01% 1031
2025
Q2 		$2.78M Sell
50,242
-713
-1% -$34.2K ﹤0.01% 1052
2025
Q1 		$2.46M Sell
50,955
-5,581
-10% -$234K ﹤0.01% 1114
2024
Q4 		$2.18M Hold
56,536
– – ﹤0.01% 1229
2024
Q3 		$2.54M Buy
56,536
+51,323
+985% +$2.07M ﹤0.01% 1197
2024
Q2 		$181K Sell
5,213
-3,870
-43% -$113K ﹤0.01% 1821
2024
Q1 		$263K Buy
9,083
+3,870
+74% +$105K ﹤0.01% 1791
2023
Q4 		$119K Hold
5,213
– – ﹤0.01% 1911
2023
Q3 		$87K Buy
5,213
+3,231
+163% +$62.7K ﹤0.01% 1994
2023
Q2 		$55K Hold
1,982
– – ﹤0.01% 1994
2023
Q1 		$46K Hold
1,982
– – ﹤0.01% 2078
2022
Q4 		$22K Hold
1,982
– – ﹤0.01% 2240
2022
Q3 		$17K Hold
1,982
– – ﹤0.01% 2286
2022
Q2 		$16K Hold
1,982
– – ﹤0.01% 2305
2022
Q1 		$50K Hold
1,982
– – ﹤0.01% 2155
2021
Q4 		$68K Hold
1,982
– – ﹤0.01% 2093
2021
Q3 		$35K Hold
1,982
– – ﹤0.01% 2325
2021
Q2 		$89K Hold
1,982
– – ﹤0.01% 2117
2021
Q1 		$51K Hold
1,982
– – ﹤0.01% 2290
2020
Q4 		$40K Buy
+1,982
New +$42.7K ﹤0.01% 2360

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Canada Life's PTGX Position: Q2 2026 in Review

Canada Life increased its Protagonist Therapeutics (PTGX) stake by 1.3% in Q2 2026, buying an estimated $63.2K and bringing the position to 48,045 shares worth $5.88M. The position accounts for 0.01% of the portfolio, ranked #715.

Canada Life first reported a position in PTGX in Q4 2020 and has held it in 23 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Canada Life held 48,045 shares of Protagonist Therapeutics worth $5.88M as of Q2 2026.
  • Canada Life bought 605 Protagonist Therapeutics shares in Q2 2026, an estimated $63.2K.
  • Protagonist Therapeutics made up 0.01% of Canada Life's portfolio in Q2 2026, its #715 holding.
  • Canada Life first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.